Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH), a clinical-stage specialty pharmaceutical company focused on improving cancer treatment outcomes through radiation therapy, announced the successful completion of its public offering, raising approximately $3.5 million in gross proceeds, before placement agent fees and other offering expenses.
The offering consisted of 2,238,800 shares of common stock and pre-funded warrants to purchase up to 4,761,200 shares of common stock. The securities were sold pursuant to a securities purchase agreement with investors, with the offering expected to close on or about March 9, 2026, subject to customary closing conditions.
Net proceeds from the offering are expected to be used to support the Company’s growth initiatives, including up to $1.5 million allocated for future marketing efforts, with the remaining proceeds designated for working capital and general corporate purposes.
Lucosky Brookman LLP served as legal counsel to the placement agent in connection with the offering. E.F. Hutton & Co. acted as the exclusive placement agent.
